中国医学创新Issue(14)：19-20,21,3.DOI:10.3969/j.issn.1674-4985.2014.14.007
中心静脉导管联合尿激酶治疗高纤维蛋白原结核性胸膜炎的疗效评价
The Therapeutic Evaluation of Central Venous Catheter Combined with Urokinase in Treatment of High Fibrinogen of Tuberculous Pleurisy
摘要
Abstract
Objective:To explore efficacy of injection of urokinas in treatment of high lever of fibrinogen tuberculous exudative pleurisy through central venous catheter to the intrapleural. Method:One hundred and sixty-two cases of tuberculous exudative pleurisy admitted from February 2010 to November 2013 in our hospital were randomly divided into 2 groups(87 cases in the treatment group and 75 cases in the control group). The two groups were treated with systemic chemotherapy(2HREZ/4HR)and prednisone 40 mg,1 times/day,the treatment group was treated closed thoracic drainage though the central venous catheter and intrapleural urokinase injection,the control group received routine thoracic puncture and drainage. Two groups were observed the time of decreased pleural effusion and complications. Result:The hydrothorax absorption after 20 days was 73.6%(64/87)in the treatment group and 37.3%(28/75)in the control group,the incidence of pleural thickening and adhesion was 34.5%(30/87)in the treatment group,and 72%(54/75)in the control group,and the differences between the two groups were all statistically significant(P<0.05). Conclusion:Venous catheter combined with urokinase conclusion centers for the treatment of high lever of fibrinogen tuberculous exudative pleurisy is more feasible than a conventional treatment method,is of great clinical value.关键词
中心静脉导管/尿激酶/纤维蛋白原/结核性胸膜炎Key words
Central venous catheter/Urokinase/Fibrinogen/Tuberculous pleurisy引用本文复制引用
章革民,孙安平,王博文,黄严春,叶俊,朱雄林,王强..中心静脉导管联合尿激酶治疗高纤维蛋白原结核性胸膜炎的疗效评价[J].中国医学创新,2014,(14):19-20,21,3.基金项目
武汉市新洲区科技局科研项目 （）
